Why now is the time to sell National Australia Bank Ltd.

National Australia Bank Ltd.'s (ASX:NAB) recent $5.5 billion capital raising is simply not enough. Here's why it's time to sell.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's no question that banking in Australia is a highly profitable oligopoly, with the four major banks controlling more than 90% of the business and consumer lending markets. National Australia Bank Ltd. (ASX: NAB) is lagging with its share of the Australian banking home loan market currently at 16%, compared to Commonwealth Bank of Australia (ASX: CBA) at 27% and Westpac Banking Corporation (ASX: WBC) at 25%.

Its household deposit market share is similarly lagging, with Commonwealth Bank of Australia leading at 29%, Westpac at 23%, Australia and New Zealand Banking Group (ASX: ANZ) at 15% and NAB at 15%.

In the past 10 years, NAB's profits have grown by just 2.2% per year from $4.3 billion to $5.3 billion, while its earnings per share (EPS) have fallen by 2.2% per year in the same time.

When you compare key financial ratios for the top four banks, they show that NAB ranks fourth in return on assets, net interest margins, cost to income and change in bad debts.

The $5.5 billion capital raising

In a recent announcement, NAB chief executive Andrew Thorburn unveiled a plan to raise capital and offload the Scotland-based Clydesdale bank through a demerger and partial float. The $5.5 billion raising is the biggest rights issue in Australian corporate history.

With around 60% of the $5.5 billion raised intended to support potential future compensation payouts to British customers, this leaves around $2.2 billion.

This capital raising is just the start of a phase of capital building by NAB, in response to looming regulatory changes requiring banks to be more resilient to shocks.

Australia's banking regulator is pushing ahead with changes that will force banks to model risk more conservatively and therefore hold more capital against mortgages. The government's financial system inquiry recommended banks be "unquestionably strong" resulting in capital imposts on all banks.

In more bad news for NAB, a slowdown in core earnings growth has resurfaced because of slower-than-expected business loan growth, margin compression, higher 'redress' costs in the UK, slower growth in banking fee income, subdued wealth and markets income, and a worse-than-expected cost outcome.

And, while the cost of wholesale funding is easing, pressure on lending and deposit rates is reducing NAB's net interest margin. When stress returns to global credit markets, wholesale funding costs will increase as well as reduce availability. The focus on loan growth has delivered strong market share gains, but when loan growth exceeds deposit growth, more expensive wholesale funding will be required to fill the funding gap.

Finally, execution risk is increasing as the group's repositioning strategy unfolds. Even if NAB can successfully deliver on its turnaround strategy, this restructuring and culture change will have significant impact on staff morale and productivity.

Poor price performance

In the past 12 months, the share price of NAB has grown by just over 4%, which is in line with growth in the S&P/ASX 200 (Index: ^AXJO)(ASX: XJO), lower than Commonwealth, and ahead of ANZ and Westpac.

Valuation

The price-to-earnings ratio for NAB is around 13, and the price-to-book ratio is 1.8. I currently value NAB at around $35, but even at this price it will not provide any reasonable future returns. That's why I think now is the time to sell.

Motley Fool contributor John Hopkins has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »